Suppr超能文献

由于醋氯芬酸有限但持续地生物转化为双氯芬酸,它对环氧化酶1具有保护作用。

Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac.

作者信息

Hinz Burkhard, Rau Thomas, Auge Daniel, Werner Ulrike, Ramer Robert, Rietbrock Stephan, Brune Kay

机构信息

Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.

出版信息

Clin Pharmacol Ther. 2003 Sep;74(3):222-35. doi: 10.1016/S0009-9236(03)00167-X.

Abstract

OBJECTIVE

The mechanism of action of aceclofenac is currently unclear. This study investigated whether biotransformation to metabolites (4'-hydroxy-aceclofenac, diclofenac, 4'-hydroxy-diclofenac) contributes to inhibitory effects on the cyclooxygenase (COX) isozymes in vitro and ex vivo.

METHODS

In vitro investigations were performed with human whole blood and human blood monocytes. A randomized crossover study was performed in volunteers receiving 100 mg aceclofenac or a sustained-release resinate formulation of 75 mg diclofenac to assess the pharmacokinetics and the ex vivo inhibition of COX-1.

RESULTS

In short-term in vitro assays, neither aceclofenac nor 4'-hydroxy-aceclofenac affected COX-1 or COX-2, whereas diclofenac and 4'-hydroxy-diclofenac inhibited both isoforms. In long-term in vitro assays, aceclofenac and 4'-hydroxy-aceclofenac suppressed both COX isoforms. However, this inhibition was paralleled by a conversion to diclofenac and 4'-hydroxy-diclofenac, respectively. Maximal plasma concentrations of diclofenac after oral administration of aceclofenac (0.39 micromol/L) or diclofenac (1.28 micromol/L) were sufficient for a greater than 97% inhibition of COX-2 (50% inhibitory concentration, 0.024 micromol/L) and a 46% (aceclofenac treatment) or 82% inhibition (diclofenac treatment) of COX-1 (50% inhibitory concentration, 0.43 micromol/L). Moreover, ex vivo COX-1-dependent thromboxane B(2) synthesis was inhibited significantly less by aceclofenac than by diclofenac.

CONCLUSIONS

Inhibition of COX isozymes by aceclofenac requires conversion into diclofenac. Although 100 mg aceclofenac yielded diclofenac concentrations substantially lower than 75 mg diclofenac, these were sufficient for a sustained block of COX-2 but caused a minor and shorter inhibition of COX-1 than 75 mg diclofenac. In conclusion, both COX-1-sparing and COX-2-inhibitory actions of aceclofenac may rest in its limited but sustained biotransformation to diclofenac.

摘要

目的

目前双氯芬酸的作用机制尚不清楚。本研究调查了其向代谢物(4'-羟基双氯芬酸、双氯芬酸、4'-羟基双氯芬酸)的生物转化是否有助于在体外和体内对环氧化酶(COX)同工酶产生抑制作用。

方法

用人全血和人血单核细胞进行体外研究。对接受100mg双氯芬酸或75mg双氯芬酸缓释树脂酸盐制剂的志愿者进行随机交叉研究,以评估药代动力学和COX-1的体内抑制作用。

结果

在短期体外试验中,双氯芬酸和4'-羟基双氯芬酸均未影响COX-1或COX-2,而双氯芬酸和4'-羟基双氯芬酸抑制了这两种同工酶。在长期体外试验中,双氯芬酸和4'-羟基双氯芬酸均抑制了两种COX同工酶。然而,这种抑制作用分别伴随着向双氯芬酸和4'-羟基双氯芬酸的转化。口服双氯芬酸(0.39μmol/L)或双氯芬酸(1.28μmol/L)后双氯芬酸的最大血浆浓度足以对COX-2产生大于97%的抑制作用(50%抑制浓度,0.024μmol/L),对COX-1产生46%(双氯芬酸治疗)或82%的抑制作用(双氯芬酸治疗)(50%抑制浓度,0.43μmol/L)。此外,双氯芬酸对体内COX-1依赖性血栓素B2合成的抑制作用明显低于双氯芬酸。

结论

双氯芬酸对COX同工酶的抑制作用需要转化为双氯芬酸。虽然100mg双氯芬酸产生的双氯芬酸浓度显著低于75mg双氯芬酸,但这些浓度足以持续阻断COX-2,但与75mg双氯芬酸相比,对COX-1的抑制作用较小且持续时间较短。总之,双氯芬酸对COX-1的保留作用和对COX-2的抑制作用可能源于其向双氯芬酸的有限但持续的生物转化。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验